The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective

被引:0
作者
Yanada, Brendan A. [1 ,2 ]
Homewood, David [1 ,3 ]
Dias, Brendan H. [1 ,3 ]
Ogluszko, Cindy [1 ]
Corcoran, Niall M. [1 ,3 ,4 ]
机构
[1] Western Hlth, Dept Urol, Footscray, Vic, Australia
[2] St Vincents Hosp Melbourne, Dept Urol, Fitzroy, Vic, Australia
[3] Univ Melbourne, Dept Surg, Parkville, Vic, Australia
[4] Victorian Comprehens Canc Ctr, Melbourne, Vic, Australia
关键词
Nonmetastatic castrate resistant prostate cancer; nmCRPC; Prostate cancer; Castrate resistance; Androgen deprivation therapy; ADT; Treatment landscape; Treatment patterns; METASTASIS; POPULATION; GUIDELINES; ANTIGEN; TIME;
D O I
10.1016/j.urolonc.2024.03.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The incidence of nonmetastatic castrate resistant prostate cancer (nmCRPC) is not well defined in contemporary practice. The aim of this study is to describe the incidence and patterns of treatment of nmCRPC over the last 6 years at a single high-volume Australian health institution. Subjects and methods: All men newly diagnosed with prostate cancer at Western Health, Melbourne from January 2016 to December 2021 were included in the study. Those diagnosed with nonmetastatic prostate cancer and treated with medical or surgical castration for biochemical failure post attempted curative therapy were retrospectively reviewed for signs of castration resistance using prostate specific antigen (PSA) and testosterone biochemical markers up until October 2022. Results: From January 2016 to December 2021, 822 patients were diagnosed with prostate cancer, 590 had localized disease, 373 underwent definitive locoregional therapy, and 31 went on to have biochemical recurrence and were commenced on androgen deprivation therapy. Twenty-five patients had undetectable PSA levels and were classified as having nonmetastatic castrate sensitive prostate cancer (nmCSPC), whilst the remaining 6 patients experienced a rising PSA and were thus classified as nmCRPC. The incidence rate of nmCRPC was 228 cases per 100,000 person-years. The median age at the time of prostate biopsy was 74 years (interquartile range [IQR] 64 - 79) in the nmCRPC group and 62 years (IQR 57 - 69) in the nmCSPC group. The median prebiopsy PSA (ng/ml) in the nmCRPC and nmCSPC groups were 27.5 (IQR 19.9 - 50.4), and 16.5 (IQR 9.0 - 26.0), respectively. The median duration from prostate cancer diagnosis to onset of nmCRPC was 24 months (IQR 17 - 29) and the median PSA doubling time was 3.4 months (IQR 2.2 - 5.7). Conclusions: Thus, nmCRPC is an uncommon disease. Further population-based studies are required to better understand the incidence of nmCRPC. (c) 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页码:175.e9 / 175.e18
页数:10
相关论文
共 21 条
[11]   Predictors of Time to Metastasis in Castration-resistant Prostate Cancer [J].
Moreira, Daniel M. ;
Howard, Lauren E. ;
Sourbeer, Katharine N. ;
Amarasekara, Hiruni S. ;
Chow, Lydia C. ;
Cockrell, Dillon C. ;
Hanyok, Brian T. ;
Aronson, William J. ;
Kane, Christopher J. ;
Terris, Martha K. ;
Amling, Christopher L. ;
Cooperberg, Matthew R. ;
Liede, Alex ;
Freedland, Stephen J. .
UROLOGY, 2016, 96 :171-176
[12]   CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A UK EPIDEMIOLOGY STUDY [J].
Morgan, C. ;
McEwan, P. ;
Chamberlain, G. ;
Cabrera, C. ;
Parry, D. .
VALUE IN HEALTH, 2010, 13 (03) :A26-A26
[13]   Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors [J].
Saad, Fred ;
Boegemann, Martin ;
Suzuki, Kazuhiro ;
Shore, Neal .
PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (02) :323-334
[14]  
Saad F, 2018, J UROLOGY, V199, pE229
[15]   Guidelines for the management of castrate-resistant prostate cancer [J].
Saad, Fred ;
Hotte, Sebastien J. .
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2010, 4 (06) :380-384
[16]   Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 [J].
Scher, Howard I. ;
Morris, Michael J. ;
Stadler, Walter M. ;
Higano, Celestia ;
Basch, Ethan ;
Fizazi, Karim ;
Antonarakis, Emmanuel S. ;
Beer, Tomasz M. ;
Carducci, Michael A. ;
Chi, Kim N. ;
Corn, Paul G. ;
de Bono, Johann S. ;
Dreicer, Robert ;
George, Daniel J. ;
Heath, Elisabeth I. ;
Hussain, Maha ;
Kelly, Wm. Kevin ;
Liu, Glenn ;
Logothetis, Christopher ;
Nanus, David ;
Stein, Mark N. ;
Rathkopf, Dana E. ;
Slovin, Susan F. ;
Ryan, Charles J. ;
Sartor, Oliver ;
Small, Eric J. ;
Smith, Matthew Raymond ;
Sternberg, Cora N. ;
Taplin, Mary-Ellen ;
Wilding, George ;
Nelson, Peter S. ;
Schwartz, Lawrence H. ;
Halabi, Susan ;
Kantoff, Philip W. ;
Armstrong, Andrew J. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) :1402-+
[17]   Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations [J].
Shore, N. ;
Oliver, L. ;
Shui, I. ;
Gayle, A. ;
Wong, O. Y. ;
Kim, J. ;
Payne, S. ;
Amin, S. ;
Ghate, S. .
JOURNAL OF UROLOGY, 2021, 205 (04) :977-986
[18]   Apalutamide and Overall Survival in Prostate Cancer [J].
Smith, Matthew R. ;
Saad, Fred ;
Chowdhury, Simon ;
Oudard, Stephane ;
Hadaschik, Boris A. ;
Graff, Julie N. ;
Olmos, David ;
Mainwaring, Paul N. ;
Lee, Ji Youl ;
Uemura, Hiroji ;
De Porre, Peter ;
Smith, Andressa A. ;
Brookman-May, Sabine D. ;
Li, Susan ;
Zhang, Ke ;
Rooney, Brendan ;
Lopez-Gitlitz, Angela ;
Small, Eric J. .
EUROPEAN UROLOGY, 2021, 79 (01) :150-158
[19]   Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer [J].
Smith, MR ;
Kabbinavar, F ;
Saad, F ;
Hussain, A ;
Gittelman, MC ;
Bilhartz, DL ;
Wynne, C ;
Murray, R ;
Zinner, NR ;
Schulman, C ;
Linnartz, R ;
Zheng, M ;
Goessl, C ;
Hei, YL ;
Small, EJ ;
Cook, R ;
Higano, CS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2918-2925
[20]   Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer [J].
Sternberg, Cora N. ;
Fizazi, Karim ;
Saad, Fred ;
Shore, Neal D. ;
De Giorgi, Ugo ;
Penson, David F. ;
Ferreira, Ubirajara ;
Efstathiou, Eleni ;
Madziarska, Katarzyna ;
Kolinsky, Michael P. ;
Cubero, Daniel I. G. ;
Noerby, Bettina ;
Zohren, Fabian ;
Lin, Xun ;
Modelska, Katharina ;
Sugg, Jennifer ;
Steinberg, Joyce ;
Hussain, Maha .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23) :2197-2206